• 목록
• 답변
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

Introduction Summary: This observational study evaluated the efficacy and tolerability of tretinoin gel 0.025% in a real-world setting among patients with acne vulgaris. Data were collected retrospectively from patient charts at a dermatology clinic over a 12-month period. The primary result measures involved changes in acne lesion figures (inflammatory and non-inflammatory) and patient-indicated tolerability. Results revealed a significant lessening in both inflammatory and non-inflammatory lesions post 12 weeks of treatment. Though early irritation was typical, it typically subsided within the first couple of weeks. This study advocates for the persistent use of tretinoin gel 0.025% as a powerful and generally well-tolerated option for acne vulgaris in real-life clinic scenarios.

Preface: Acne vulgaris is a common chronic inflammatory skin condition affecting a significant portion of the global population, primarily adolescents and young adults. Care options differ widely, covering from topical retinoids to oral antibiotics and systemic interventions. Tretinoin, being a topical retinoid, is a commonly utilized and solidly proven treatment for acne because of its skill in decreasing sebum generation, stimulating epidermal cell regeneration, and reducing inflammation. While numerous clinical trials have demonstrated the efficacy of tretinoin, real-world observational studies are crucial to assess its effectiveness and tolerability in diverse patient populations and under routine clinical practice conditions. This report aimed to retrospectively evaluate the clinical effects and tolerability of tretinoin gel 0.025% in patients with acne vulgaris handled at a skin care clinic.

Techniques: This backward-looking observational research encompassed adult patients (18 years and above) identified with acne vulgaris who received tretinoin gel 0.025% as the main therapy method from January 1, 2022, to December 31, 2022, at one dermatology center. Patient records were examined to gather information on demographics (age, gender), baseline acne intensity (evaluated via a modified Global Acne Grading System [mGAGS]), therapy length, alterations in lesion numbers (inflammatory and non-inflammatory) at starting point, 4 weeks, 8 weeks, and 12 weeks, and patient-noted tolerance (evaluated through doctor notes recording patient issues). Records of co-administered medications were furthermore included.

The mGAGS score was calculated by summing the scores for inflammatory lesions (papules, pustules, nodules, cysts) and non-inflammatory lesions (comedones). Each lesion type was assigned a score based on its severity and number. Acceptability was gauged based on clinician notes of patient-documented side effects, including dryness, irritation, erythema, and peeling. The intensity of these negative events was classified as mild, moderate, or severe.

Statistical analysis was performed using descriptive statistics to summarize the demographic and clinical characteristics of the study population. Paired t-tests were employed to evaluate lesion tallies at baseline and at each monitoring point. Shifts in lesion tallies were also assessed using repeated measures ANOVA. The association between baseline acne severity and treatment response was assessed using correlation analysis.

Conclusions: A total of 100 patients (62 females, 38 males) with a mean age of 24.5 ± 5.2 years were included in the study. The mean initial mGAGS index was 18.7 ± 6.3. At the beginning, the average figure of inflammatory lesions was 9.2 ± 4.1 and the average figure of non-inflammatory lesions was 9.5 ± 3.8.

Marked reductions in both inflammatory and non-inflammatory lesion figures were identified at every subsequent point against baseline (p<0.001 for all assessments). The mean reduction in inflammatory lesions at 12 weeks was 7.1 ± 2.9, and the mean reduction in non-inflammatory lesions was 6.8 ± 2.7. Repeated measures ANOVA revealed a substantial time influence on both inflammatory and non-inflammatory lesion tallies (p<0.001 for both).

Early irritation was documented by 72% of patients, with the bulk encountering mild irritation (60%). Moderate irritation was noted by 12% of patients, and severe irritation was noted by just 10% of patients. The greater part of patients with mild to moderate irritation reported subsidence of symptoms within 4 weeks of initiating treatment. No participants ceased treatment due to inadaptability.

Examination: This study presents real-life evidence promoting the efficiency and endurance of tretinoin gel 0.025% in treating acne vulgaris. The substantial drop in both inflammatory and non-inflammatory lesion tallies noted in this investigation matches findings from earlier clinical tests. The high frequency of early irritation is also aligned with the established side effect profile of tretinoin. However, the fact that the majority of patients experienced only mild irritation and that the irritation generally resolved within a few weeks suggests that tretinoin gel 0.025% is generally well-tolerated.

The retroactive nature of this analysis is a shortcoming, as it is exposed to potential biases related to data assembly and omitted data. In addition, the study was executed at one location, which may curb the transferability of the outcomes to other cohorts. Future planned researches with greater participant numbers and multiple facilities are necessary to further affirm these findings.

End Note: This observational investigation endorses the utilization of tretinoin gel 0.025% as an efficient and typically well-endured treatment for acne vulgaris in everyday clinic scenarios. While beginning irritation is widespread, it is normally mild and passing. Clinicians need to advise patients about the risk of preliminary irritation and guide them on tactics to reduce these unwanted effects. More investigation is required to examine the long-range potency and security of tretinoin gel 0.025% in different populations.